Failed dementia drug gets a second chance
Biogen, a multinational biotechnology company, and Eisai, a Japanese pharmaceutical company, are planning to file for Food and Drug Administration (FDA) approval for an Alzheimer’s drug that had mixed results in clinical trials. Can this...
Read More